Mark Zuckerberg, CEO of Meta, has hired three researchers from OpenAI to bolster his company’s work on artificial intelligence. This strategic move aims to guide Meta Platforms through its current AI challenges. The social-media corporation brought aboard Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai, all of whom previously held positions at OpenAI’s branch in Zurich, as per sources privy to this information. These individuals established OpenAI’s location in Zurich towards the end of last year. Prior to their time at OpenAI, they collaborated closely within Google DeepMind, which is the organization’s artificial intelligence division. A representative from OpenAI verified that the three scientists have departed from the organization. Zuckerberg has been on an intense recruiting drive To correct the company’s AI initiatives following the underwhelming reception of its most recent model, he has sometimes proposed giving researchers up to $100 million to become part o...
Tuhura Biosciences' stock price jumped by 20.2% during post-market hours on Monday following approval from the shareholders of both companies for the suggested merger between Tuhura Biosciences and Kineta, Inc., as well as other associated resolutions, which were discussed at separate shareholder gatherings earlier that day.
The stock ended Monday’s normal trading session marginally below at $2.53, decreasing by 0.8%.
The merger will integrate Tuhura’s clinical-stage immuno-oncology platform, featuring its advanced Phase 3 ready main product IFx-2.0, along with Kineta’s Vista-inhibiting antibody KVA12123 and an early stage CD27-focused treatment.
The combined entity intends to tackle both inherent and developed resistance to present cancer immunotherapies.
The shareholders of Tuhura endorsed crucial proposals, such as raising the number of authorized shares to 200 million and relocating the corporation’s incorporation to Delaware.
The Kineta shareholders likewise endorsed the merger conditions during a distinct special assembly.
The deal is anticipated to be completed shortly, provided all outstanding conditions have been met or waived.
Tuhura plans to launch a randomized Phase 3 clinical trial combining IFx-2.0 with Keytruda (pembrolizumab) as the initial treatment option for patients suffering from advanced or metastatic Merkel cell carcinoma.
Kineta's Vista therapy, KVA12123, had initially advanced into Phase 1/2 clinical trials for solid tumors but was halted in 2024 due to a company overhaul involving layoffs aimed at cutting costs and conserving capital.
On AppStoreOfficialID, retail sentiment remained 'bullish' despite an 'exceptionally high' volume of messages.
A customer mentioned that Tuhura had the potential to trade above $10 and potentially surpass valuation of over $15.
A fellow user observed that recently, the stock has been progressively rising towards the end of each session.
Tuhura's stock has dropped by 38.4% year-to-date in 2025.
To request updates or corrections, send an email to newsroom@appstoreofficialid.com.